In peptide API campaigns where D-serine is incorporated at non-standard positions, D-serine methyl ester hydrochloride (CAS 5874-57-7, molecular weight 155.58 g·mol⁻¹) is used as a carboxyl-protected fragment in solution-phase segment condensation rather than as a free acid in solid-phase peptide synthesis. The methyl ester suppresses aspartimide-like side reactions and permits orthogonal deprotection under mild alkaline conditions after amide bond formation. The material is released after non-aqueous titration with perchloric acid; the assay limit is 98.0–101.0% on the dried basis. Water content is held below 0.5% by Karl Fischer titration to prevent premature hydrolysis of the methyl ester during storage and dispensing. A validated coupling sequence typically begins with dissolution of 1.0 eq D-Ser-OMe·HCl in anhydrous N,N-dimethylformamide at 0–5 °C, followed by dropwise addition of N,N-diisopropylethylamine (3.0 eq) and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.1 eq). The activated mixture is stirred for 15 min at 0–5 °C, then added over 30 min to a solution of the N-protected peptide acid (1.0 eq) in the same solvent at 15–20 °C. Coupling proceeds under nitrogen for 16–24 h at 20–25 °C, with conversion monitored by UPLC-MS using an Acquity BEH C18 column and a gradient of 5–95% acetonitrile in water containing 0.1% formic acid. The methyl ester is then cleaved without disturbing the newly formed amide bond by treatment with lithium hydroxide (1.2 eq) in a 3:1 tetrahydrofuran/water mixture at 0–5 °C, maintaining the pH between 10.5 and 11.0 with a stop-flow pH control loop on a jacketed glass reactor. Crude peptide solutions are concentrated by rotary evaporation below 35 °C, precipitated in cold methyl tert-butyl ether, and purified by preparative reverse-phase HPLC using a C18 column with 100 mm internal diameter and 10 µm particles. Final peptide purity is expressed as area percent at 214 nm, and the acceptance limit is ≥ 98.0% by HPLC according to USP <621>. Residual solvent testing follows USP <467> for DMF, THF, methanol, and methyl tert-butyl ether. The downstream end products are D-Ser-containing peptide APIs and research-grade peptide libraries used in antimicrobial and receptor-binding studies.

Why Does the Hydrochloride Salt Form Suppress Racemization in D-Cycloserine Ring Closure?

The hydrochloride counterion provides a protonated α-amine that avoids spontaneous oxazolidinone formation during the initial hydroxamic acid preparation. In the two-vessel route, D-Ser-OMe·HCl (1.0 mol) is suspended in methanol at 0–5 °C, and hydroxylamine hydrochloride (1.05 mol) is added. Sodium methoxide solution (25 wt% in methanol, 2.0 mol) is metered in over 2 h while maintaining the internal temperature below 8 °C. The resulting D-serine methyl hydroxamate intermediate is aged for 4 h at 5–10 °C, then the temperature is raised to 30 °C for cyclization to D-cycloserine. The pH is held at 8.5–9.0 during ring closure by controlled addition of sodium methoxide. Crude D-cycloserine is isolated by cooling to 0 °C, filtration through a 0.45 µm PES membrane, and recrystallization from methanol/water (1:1) with an activated carbon treatment. The final API is dried in a vacuum tray dryer at 45 °C and −0.08 MPa for 12 h. Compliance with the Ph. Eur. monograph for cycloserine requires an HPLC assay of 95.0–105.0% on the dried basis, a specified optical rotation, and an ethyl acetate residual solvent limit of 5000 ppm under ICH Q3C. The process limit for residual methanol is 3000 ppm. This route is preferred when enantiomeric purity of the D-isomer must exceed 99.5%, because the ester salt is easier to recrystallize than the free amino acid from methanol. Published pilot-scale data above 200 L for this specific configuration is limited.

N-Boc-D-serine methyl ester prepared from the hydrochloride under biphasic Schotten–Baumann conditions is a standard entry point for enantiopure D-serinal intermediates in asymmetric synthesis. The hydrochloride is partitioned between dichloromethane and saturated aqueous sodium bicarbonate, and di-tert-butyl dicarbonate (1.05 eq) is charged at 0–5 °C. The biphasic mixture is stirred for 6–8 h at 20–25 °C, and the organic layer is dried over anhydrous sodium sulfate to a water content of 0.1%. Subsequent reduction to D-serinal uses diisobutylaluminium hydride (1.5 eq, 1.0 M in dichloromethane) added dropwise to the ester solution at −78 °C under an argon atmosphere in a jacketed low-temperature reactor with a −80 °C silicon oil circulation bath. The reduction is quenched by slow addition of saturated aqueous Rochelle salt at −78 °C, warmed to 25 °C over 2 h, and filtered through Celite to remove aluminum salts. The resulting D-serinal is used immediately as a chiral aldehyde building block for diastereoselective additions without isolation, because aldehyde racemization at the α-carbon is accelerated above −20 °C. Downstream products include chiral amino alcohols, oxazolidines, and β-amino alcohols used in experimental antiviral and CNS-targeted small molecules. The process is governed by ISO 9001 for research chemical supply, with residual dichloromethane and dichloromethane-derived impurities monitored by gas chromatography according to USP <467>; the release limit for dichloromethane is 600 ppm. Water ingress during DIBAL-H addition causes exothermic hydrogen evolution and reduces yield, so the reactor headspace is purged with argon at 2 L·min⁻¹ and the solvent is dried over activated 4 Å molecular sieves before use.

When the Methyl Ester Is Used as a Stable Precursor in Coupled Oxidase Assays

Enzymatic methods for D-serine quantification in cerebrospinal fluid microdialysates often require the free amino acid as the oxidase substrate, but the free amino acid is hygroscopic and less convenient for long-term reagent kit storage. The hydrochloride methyl ester provides a crystalline precursor that is hydrolyzed in situ by porcine liver esterase (EC 3.1.1.1) or by the assay matrix after reconstitution. In a coupled assay, D-Ser-OMe·HCl is dissolved in phosphate-buffered saline at pH 7.4 to a stock concentration of 10 mM, then diluted to substrate concentrations between 0.1 mM and 10 mM. Hydrolysis to free D-serine is confirmed by o-phthaldialdehyde derivatization and reverse-phase HPLC with fluorescence detection, using a C18 column and gradient elution with methanol and 0.1 M sodium acetate at pH 6.5. The free D-serine is then oxidized by D-amino acid oxidase from porcine kidney (EC 1.4.3.3) to hydroxypyruvate and hydrogen peroxide, with peroxide detected via horseradish peroxidase and Amplex Red at 570 nm. The linear range of the assay in microplate format is typically 0.5–50 µM after hydrolysis. Diagnostic use of such cassette modules falls under ISO 13485:2016 for medical device quality management and requires CLSI EP17 validation for the limit of blank and limit of detection. The methyl ester form itself is not a direct substrate for D-amino acid oxidase, and any unhydrolyzed ester remaining under short incubation times will be underrepresented in the assay; therefore the initial esterase step is run at 37 °C for 30 min. This kinetic delay is a critical processing limitation when the assay is transferred from microplate to clinical chemistry analyzers with cycle times below 20 min.

For neuroscience research supply, the hydrochloride is released with enantiomeric purity that exceeds standard amino acid specifications. Typical release criteria include specific optical rotation [α]D20 = −4.5° ± 0.5° (c = 1, methanol) and chiral HPLC area percent ≥ 99.5% for the D-isomer. The material is weighed in a dry nitrogen glovebox with relative humidity < 10%, dissolved in artificial cerebrospinal fluid at 1 mM, pH-adjusted to 7.4 with sodium bicarbonate, and sterile-filtered through a 0.22 µm PVDF membrane prior to electrophysiology slice work. In rodent microdialysis, the ester form has been evaluated as a more lipophilic delivery form of D-serine, but published pharmacokinetic data for this specific ester are limited; hydrolysis by plasma esterases is expected but has not been fully characterized across strains. The research endpoint is activation of the glycine modulatory site on NMDA receptors, and the product is not classified as an API for human use. Documentation is limited to research-grade certificates of analysis under ISO 9001 and REACH registration for the substance itself. No pharmacopoeial monograph exists for this ester, so each batch is tested for loss on drying at 60 °C for 2 h and for residual methanol by USP <467> with a limit of 3000 ppm.

Chiral Oxazoline Ligand Precursor Supply for Enantioselective Catalysis

Reduction of D-Ser-OMe·HCl to D-serinol precedes the assembly of chiral 2-oxazoline ligands used in asymmetric transition-metal catalysis. Sodium borohydride (2.2 eq) is added portion-wise to a suspension of the ester hydrochloride in tetrahydrofuran/ethanol (4:1) at 0 °C, followed by lithium chloride (2.0 eq) to enhance reducing power. The mixture is warmed to 25 °C over 3 h, then quenched with saturated ammonium chloride and extracted with ethyl acetate. D-Serinol is isolated as a pale oil before distillation. Cyclization with triethyl orthoacetate (1.2 eq) and a catalytic amount of p-toluenesulfonic acid (0.05 eq) in dichloromethane at 40 °C yields the corresponding 2-oxazoline. When the oxazoline is further elaborated into bis(oxazoline) ligands, the final chiral ligand is used in palladium-catalyzed asymmetric allylic alkylation and copper-catalyzed cyclopropanation. The ligand is purified by silica gel column chromatography with elution at Rf 0.35 in 1:1 ethyl acetate/hexane. Transition-metal residues are controlled to < 10 ppm for Pd and < 25 ppm for Cu by ICP-MS, because residual metals poison downstream asymmetric hydrogenation steps. Compliance for such non-GMP intermediates is typically limited to ISO 9001 batch traceability and REACH registration for methanol, dichloromethane, and ethyl acetate. The operational boundary is that lithium chloride must be anhydrous; water levels above 1% suppress borohydride reduction and generate hydrogen gas, requiring reactor inerting and explosion-proof equipment.